161 related articles for article (PubMed ID: 16080532)
1. Soluble CD44v6 is not a sensitive tumor marker in patients with head and neck squamous cell cancer.
Andratschke M; Chaubal S; Pauli C; Mack B; Hagedorn H; Wollenberg B
Anticancer Res; 2005; 25(4):2821-6. PubMed ID: 16080532
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma.
Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH
Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M
Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810
[TBL] [Abstract][Full Text] [Related]
5. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073
[TBL] [Abstract][Full Text] [Related]
6. Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy.
Chang SM; Xing RD; Zhang FM; Duan YQ
Oral Dis; 2009 Nov; 15(8):570-2. PubMed ID: 19563418
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
[TBL] [Abstract][Full Text] [Related]
8. CYFRA 8/18 in head and neck cancer.
Maass JD; Niemann AM; Lippert BM; Gottschlich S; Folz BJ; Werner JA
Anticancer Res; 1999; 19(4A):2699-701. PubMed ID: 10470223
[TBL] [Abstract][Full Text] [Related]
9. Cut-off value determination of CYFRA 21-1 for squamous cell carcinomas of the head and neck (SCCHN).
Niemann AM; Goeroegh T; Gottschlich S; Lippert BM; Werner JA
Anticancer Res; 1997; 17(4B):2859-60. PubMed ID: 9329547
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.
Ozturk B; Coskun U; Sancak B; Yaman E; Buyukberber S; Benekli M
Int Immunopharmacol; 2009 May; 9(5):645-8. PubMed ID: 19249390
[TBL] [Abstract][Full Text] [Related]
11. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
Afify A; Lynne LC; Howell L
Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
[TBL] [Abstract][Full Text] [Related]
12. CD44s and CD44v6 expression in head and neck epithelia.
Mack B; Gires O
PLoS One; 2008; 3(10):e3360. PubMed ID: 18852874
[TBL] [Abstract][Full Text] [Related]
13. Salivary soluble CD44: a potential molecular marker for head and neck cancer.
Franzmann EJ; Reategui EP; Carraway KL; Hamilton KL; Weed DT; Goodwin WJ
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):735-9. PubMed ID: 15767360
[TBL] [Abstract][Full Text] [Related]
14. Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.
Kopp R; Classen S; Wolf H; Gholam P; Possinger K; Wilmanns W
Anticancer Res; 2001; 21(4B):2995-3000. PubMed ID: 11712800
[TBL] [Abstract][Full Text] [Related]
15. The significance of Tenascin-C serum level as tumor marker in squamous cell carcinoma of the head and neck.
Pauli C; Stieber P; Schmitt UM; Andratschke M; Hoffmann K; Wollenberg B
Anticancer Res; 2002; 22(5):3093-7. PubMed ID: 12530049
[TBL] [Abstract][Full Text] [Related]
16. Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.
Kuropkat C; Plehn S; Herz U; Dünne AA; Renz H; Werner JA
Anticancer Res; 2002; 22(4):2221-7. PubMed ID: 12174907
[TBL] [Abstract][Full Text] [Related]
17. The soluble interleukin-2 receptor--a marker for squamous cell carcinoma of the upper aerodigestive tract.
Gottschlich S; Görögh T; Lippert BM; Niemann AM; Folz BJ; Werner JA
Anticancer Res; 1997; 17(4B):2921-2. PubMed ID: 9329564
[TBL] [Abstract][Full Text] [Related]
18. [Detection of serum soluble fragments of cytokeratins 8 and 18 in patients with squamous epithelial carcinomas of the upper aerodigestive tract].
Maass JD; Niemann AM; Lippert BM; Gottschlich S; Folz BJ; Werner JA
Laryngorhinootologie; 1997 Sep; 76(9):554-8. PubMed ID: 9417185
[TBL] [Abstract][Full Text] [Related]
19. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer.
Kawano T; Nakamura Y; Yanoma S; Kubota A; Furukawa M; Miyagi Y; Tsukuda M
Auris Nasus Larynx; 2004 Mar; 31(1):35-41. PubMed ID: 15041052
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of CD44 isoform expression in thymic epithelial neoplasms.
Sonobe S; Miyamoto H; Nobukawa B; Izumi H; Futagawa T; Ishikawa N; Yamazaki A; Uekusa T; Abe H; Suda K
Cancer; 2005 May; 103(10):2015-22. PubMed ID: 15830350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]